Nobuhiro Takagi

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Norihiro Nishimoto, Kimio Terao, Toru Mima et al. · Blood · 2008 · 810 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

Nobuhiro Takagi, Masahiko Mihara, Yoichiro Moriya et al. · Arthritis & Rheumatism · 1998 · 273 citations

Medicine, Immunology, Pathology +16

Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.

Norihiro Nishimoto, Kazuyuki Yoshizaki, Keiji Maeda et al. · PubMed · 2003 · 205 citations

Medicine, Pharmacokinetics, Pharmacology +17

IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice

Masahiko Mihara, Nobuhiro Takagi, Yasuaki Takeda et al. · Clinical & Experimental Immunology · 1998 · 146 citations · Full text

Medicine, Immunology, Pathology +13

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Norihiro Nishimoto, Koichi Amano, Yasuhiko Hirabayashi et al. · Modern Rheumatology · 2013 · 120 citations

Medicine, Clinical Sciences, Pharmacotherapy +17